Heart Test Laboratories Inc

Research Heart Test Laboratories Inc (HSCS) on Bullrun: market cap USD 9.57M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 9.57M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 4.35K-USD 8.77M-USD 7.42M56.8%-9.34USD 1.10MUSD 876.24KUSD 205.17K
FY2024USD 18.60K-USD 6.61M-USD 6.13M67.3%-18.74USD 5.81MUSD 2.90MUSD 7.32M
FY2023USD 5.15K-USD 6.35M-USD 5.79M45.7%-80USD 1.66MUSD 2.00MUSD 230.56K
FY2022USD 14.37K-USD 4.83M-USD 3.65M45.1%-1.45USD 918.26KUSD 1.19M-USD 6.06M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 9.57Mn/an/an/a
20252025-12-31USD 9.82Mn/an/an/a
20242024-12-31USD 3.74Mn/an/an/a
20232023-12-29USD 10.88Mn/an/an/a
20222022-12-30USD 6.90Mn/an/an/a

About Heart Test Laboratories Inc

HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Heart Test Laboratories Inc's market cap?

Heart Test Laboratories Inc's market capitalization is USD 9.57M.

What does Heart Test Laboratories Inc do?

HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic ECG management platform.